Merck innovation fund joins $75M funding in AI pathology research startup

PathAI, a developer of artificial intelligence technology for use in pathology research, closed its Series B investment round Nov. 4, including participation from the Merck Global Health Innovation Fund and Bristol-Myers Squibb.

The infusion from the two pharmaceutical giants brings PathAI's total Series B funding to $75 million; the startup initially raised $60 million in the round in April. Since its 2016 founding, the Boston-based PathAI has now raised more than $90 million.

The funding will support PathAI's growing capabilities in clinical development. As David Rubin, PhD, managing director of the Merck innovation fund, explained in a news release, "[PathAI's] industry-leading work incorporating artificial intelligence into digital pathology holds the potential to change the way we diagnose and treat cancer."

More articles on AI:
Geisinger, Mayo Clinic, IBM among 25 participants chosen for CMS AI challenge
Patients don't trust AI — here's how providers can change that
How Facebook, NYU School of Medicine are using AI to speed MRI readings

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months